Aethlon Medical Announces the Appointment of Laszlo Radvanyi, Ph.D. to its Scientific Advisory Board

  Aethlon Medical Announces the Appointment of Laszlo Radvanyi, Ph.D. to its
                          Scientific Advisory Board

PR Newswire

SAN DIEGO, Jan. 17, 2013

SAN DIEGO, Jan. 17, 2013 /PRNewswire/ --Aethlon Medical, Inc. (OTCBB: AEMD),
the pioneer in developing selective therapeutic filtration devices to address
infectious disease, cancer and other life-threatening conditions, announced
today that Laszlo Radvanyi, Ph.D., an Associate Professor in the Department of
Melanoma Medical Oncology Research at the University of Texas MD Anderson
Cancer Center in Houston, has joined its Scientific Advisory Board.

"I am excited to be a part of Aethlon's Scientific Advisory Board and its
quest to develop clinical methods to remove exosomes from cancer patients.
Exosomes are emerging as key long distance communicators of immune suppression
in cancer throughout the body, especially through suppressive myeloid cells,
and evidence is accumulating on the beneficial effects of exosome removal on
anti-tumor immune responses," stated Dr. Radvanyi.  "I am especially
interested in working with Aethlon in developing research projects and
clinical trials with the Hemopurifier as a synergistic therapywith other
forms of immunotherapy in cancer patients to improve response rates and
durability. Aethlon's technology removing exosomes in a non-invasive, simple,
and safe fashion promises to catalyze a whole new approach to immunotherapy
trials in cancer in the near future."

Dr. Radvanyi received his Ph.D. in clinical biochemistry from the University
of Toronto. His main research area is tumor immunology studying immune
regulation in cancer and identifying new antigens as targets for anti-cancer
T-cell therapy. After completing postdoctoral work in Toronto and at Harvard
University in Boston at the Joslin Diabetes Center, Dr. Radvanyi joined the
Immunology Group at Sanofi-Pasteur in Toronto in 2000 as a Senior Scientist
where he helped lead an antigen discovery program that led to the discovery of
a group of over-expressed breast cancer-specific genes that are candidates for
antigen-specific vaccines against breast cancer. In 2005, Dr. Radvanyi joined
the faculty of the University of Texas, MD Anderson Cancer Center, where he
also holds the additional appointment as Associate Professor, Department of
Breast Medical Oncology, Division of Cancer Medicine.

"We are honored to have Dr. Radvanyi participate as a member of our Scientific
Advisory Board and look forward to receiving his guidance as we advance our
cancer treatment endeavors," stated Aethlon Medical Chairman and Chief
Executive Officer, Jim Joyce.

MD Anderson is one of the world's premier cancer centers. For the sixth year
in a row, and the ninth time in the past 11 years, MD Anderson Cancer Center
earned the No. 1 spot in U.S. News & World Report's annual rankings of the
best hospitals for cancer care. Since the survey began in 1990, MD Anderson
has been ranked every year as one of the top two hospitals in the nation for
cancer care.

About Aethlon Medical

Aethlon Medical creates innovative medical devices that address unmet medical
needs in cancer, infectious disease, and other life-threatening conditions.
Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides
the basis for a new class of devices the rapid, yet selective removal of
disease promoting particles from the entire circulatory system. At present,
The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to
address infectious disease and cancer, and a medical device being developed
under a 5-year contract with Defense Advanced Research Projects Agency (DARPA)
to reduce the incidence of sepsis in combat-injured soldiers. For more
information, please visit

About The Aethlon Hemopurifier®

The Aethlon Hemopurifier® is a first-in-class medical device that selectively
targets the rapid clearance of infectious viral pathogens and
immunosuppressive proteins from the entire circulatory system. In the
treatment of Hepatitis C virus (HCV), human studies have demonstrated that
Hemopurifier® therapy may improve immediate, rapid and sustained virologic
response rates when administered in the first few days of standard-of-care
drug therapy. In addition to accelerating viral load depletion,
post-treatment analysis of the Hemopurifier® has documented the capture of up
to 300 billion HCV copies of HCV during a single six-hour treatment. Access
to Hemopurifier® therapy is available on a compassionate-use basis through the
Medanta Medicity Institute (Medicity), a leading center for medical tourism in
India. The Medicity is offering treatment access to infected individuals who
previously failed or subsequently relapsed standard-of-care drug regimens.
The Hemopurifier® is also being offered as a salvage therapy to infected
individuals who suffer a viral breakthrough during standard-of-care therapy.
U.S. studies of the Hemopurifier® are currently pending approval of an IDE
submitted to FDA. 

The Aethlon Hemopurifier® and Cancer

In addition to the opportunity to address a broad-spectrum of infectious viral
pathogens, the Hemopurifier® has been discovered to capture tumor-derived
exosomes underlying several forms of cancer. Tumor-derived exosomes have
recently emerged to be a vital therapeutic target in cancer care. These
microvesicular particles suppress the immune response in cancer patients
through apoptosis of immune cells and their quantity in circulation correlates
directly with disease progression. Beyond possessing immunosuppressive
properties, tumor-derived exosomes facilitate tumor growth, metastasis, and
the development of drug resistance. By addressing this unmet medical need,
the Hemopurifier® is positioned as an adjunct to improve established cancer
treatment regimens.

Certain statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, that the FDA will not approve the
initiation of the Company's clinical programs or provide market clearance of
the company's products, future human studies whether revenue or non-revenue
generating from either compassionate use or non-compassionate use of the
Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to
improve patient responsiveness to established cancer or hepatitis C therapies
or as a standalone cancer or hepatitis C therapy, the Company's ability to
raise capital when needed, the Company's ability to complete the development
of its planned products, the Company's ability to manufacture its products
either internally or through outside companies and provide its services, the
impact of government regulations, patent protection on the Company's
proprietary technology, product liability exposure, uncertainty of market
acceptance, competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a variety of
factors, including the risks associated with the effect of changing economic
conditions and other risk factors detailed in the Company's Securities and
Exchange Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise.


James A. Joyce
Chairman and CEO
858.459.7800 x301

Jim Frakes
Chief Financial Officer
858.459.7800 x300

Marc Robins

SOURCE Aethlon Medical, Inc.

Press spacebar to pause and continue. Press esc to stop.